CN111528479A - Probiotics and prebiotics composition for relieving atopic dermatitis function and application - Google Patents
Probiotics and prebiotics composition for relieving atopic dermatitis function and application Download PDFInfo
- Publication number
- CN111528479A CN111528479A CN202010413680.5A CN202010413680A CN111528479A CN 111528479 A CN111528479 A CN 111528479A CN 202010413680 A CN202010413680 A CN 202010413680A CN 111528479 A CN111528479 A CN 111528479A
- Authority
- CN
- China
- Prior art keywords
- cfu
- oligosaccharide
- atopic dermatitis
- lactobacillus
- probiotics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012438 Dermatitis atopic Diseases 0.000 title claims abstract description 59
- 201000008937 atopic dermatitis Diseases 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 239000006041 probiotic Substances 0.000 title claims abstract description 45
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 45
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 41
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 33
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 33
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 32
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 32
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 32
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 32
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 32
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 31
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 31
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 31
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 29
- 241000186869 Lactobacillus salivarius Species 0.000 claims abstract description 29
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 29
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 27
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 24
- 235000013305 food Nutrition 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 15
- 235000019722 synbiotics Nutrition 0.000 abstract description 15
- 241000894006 Bacteria Species 0.000 abstract description 13
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 11
- 230000000529 probiotic effect Effects 0.000 abstract description 10
- 238000011160 research Methods 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 230000000968 intestinal effect Effects 0.000 abstract description 7
- 230000001105 regulatory effect Effects 0.000 abstract description 6
- 230000004083 survival effect Effects 0.000 abstract description 4
- 241000186660 Lactobacillus Species 0.000 abstract description 2
- 229940039696 lactobacillus Drugs 0.000 abstract 1
- 230000006870 function Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 11
- 208000010668 atopic eczema Diseases 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000000172 allergic effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000003979 eosinophil Anatomy 0.000 description 5
- 235000013350 formula milk Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 241001112696 Clostridia Species 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000000222 eosinocyte Anatomy 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 244000005714 skin microbiome Species 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000226932 Bifidobacterium bifidum BGN4 Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229940064062 alpha-glucan oligosaccharide Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000008576 chronic process Effects 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/181—Salivarius
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a probiotic and prebiotic composition for relieving atopic dermatitis and application thereof, wherein the composition comprises the following raw materials in percentage by weight: lactobacillus acidophilus 1011～1014CFU/kg, Bifidobacterium lactis 1011～1014CFU/kg Bifidobacterium bifidum 1011～1014CFU/kg, Lactobacillus casei 1011～1014CFU/kg, Lactobacillus salivarius 1011～1014CFU/kg, fructo-oligosaccharide 50-500 g/kg, and galacto-oligosaccharide in balance. The Synbiotic preparation is prepared from Bifidobacterium lactis and Lactobacillus acidophilusThe probiotic and prebiotic composition consists of bacteria, lactobacillus casei, bifidobacterium bifidum, lactobacillus salivarius, fructo-oligosaccharide and galacto-oligosaccharide and has the function of relieving atopic dermatitis, and clinical research proves that the probiotic and prebiotic composition has the effect of relieving atopic dermatitis; the synbiotic preparation can improve the intestinal environment and restore the intestinal-skin stable state by regulating the micro-ecological balance of the intestinal tract of a human body. The high-quality prebiotics compounded by the invention can improve the colonization rate and survival rate of probiotics in intestinal tracts.
Description
Technical Field
The invention relates to the technical field of functional foods, in particular to a composition of probiotics and prebiotics for relieving atopic dermatitis and application thereof.
Background
The skin is where human symbiotic colonies are most abundant, and contains over 1000 different bacteria from 19 different phyla. Normally, the human body micro-ecology is influenced by the 'intestine-brain-skin axis', that is, there is a dynamic balance among microorganisms of the skin, intestinal microorganisms and hosts, and the balance is commonly involved in the metabolism, immunity, nutrition and skin health, but the balance is easily influenced by genetic, environmental, infection and mental factors, so that skin diseases such as atopic dermatitis, acne and herpes are caused.
Atopic Dermatitis (AD), also known as eczema, is a chronic, recurrent, inflammatory, pruritic skin disease that is manifested primarily as dry skin, widespread erythema, papules, desquamation and persistent itching, which severely affects quality of life. The disease usually begins in infancy, the number of patients before the age of l is about 50% of all patients, the disease can be delayed to adults in chronic process, the prevalence rate of atopic dermatitis is increased year by year for 20 years, and the disease is higher in urban areas than in rural areas. The skin barrier function of atopic dermatitis patients is damaged, the content of Natural Moisturizing Factor (NMF) in the skin is reduced, the pH of the skin surface is increased, the antibacterial effect is reduced to cause the skin micro-ecology change, and the micro-ecology abnormality damages the skin barrier through various paths in turn. The research shows that the diversity of skin microflora of atopic dermatitis patients is reduced, the staphylococcus aureus colonization on the skin surface is obviously increased, and in addition, the skin surface of AD patients is also accompanied with the change of other microflora, such as propionibacterium, streptococcus, acinetobacter, malassezia and the like, which are closely related to the AD pathogenesis and trigger Th2 immune response through different ways.
The traditional method for treating atopic dermatitis is mainly based on drug local treatment, common drug types comprise glucocorticoids, antihistamines, antibiotics, calcineurin inhibitors, immunosuppressants and the like, and although the curative effect of the drug treatment is effective in a short term, the drug treatment is easy to relapse, probably because the drugs have certain toxicity, destroy the flora homeostasis of the skin epidermis, show that beneficial bacteria are reduced and harmful bacteria are increased, and further cause the relapse. Probiotics and prebiotics can be used to increase regulatory T cell function and decrease serum IgE and eosinophil counts; regulating the level of quinolinic canine urokinase and gamma-aminobutyric acid by intestinal bacteria to relieve itching symptoms; the lactic acid is secreted, the pH value of the skin environment is reduced, the colonization of staphylococcus aureus is inhibited, the antibacterial effect is achieved, and the probiotics and prebiotics can relieve the symptoms of atopic dermatitis through the mechanisms.
The invention discloses a prebiotics functional formula for regulating the unbalance of skin flora and relieving eczema, and relates to a prebiotics formula consisting of Chinese mugwort, essential oil, inulin and alpha-glucan oligosaccharide for relieving eczema, wherein the prebiotics function formula plays a role through the synergistic effect of the prebiotics. The invention of Chinese patent publication No. CN 110214014A discloses the use of probiotics in the treatment and/or prevention of atopic dermatitis, and relates to a probiotic composition, namely, bifidobacterium lactis CECT 8145, bifidobacterium longum CECE 7374 and/or lactobacillus casei CECT 9104, for the treatment and/or prevention of atopic dermatitis, and the invention is only limited in the scope of protection to the above two or three strains. The invention discloses a functional probiotic solid beverage and a preparation method thereof, wherein the formula of the probiotic solid beverage comprises 40% of maltodextrin, 20% of microcrystalline cellulose, 10% of anhydrous glucose, 10% of fructo-oligosaccharide, 10% of stachyose, 5% of bifidobacterium longum, 2% of bifidobacterium lactis, 1% of lactobacillus acidophilus, 1% of lactobacillus casei and 1% of lactobacillus rhamnosus.
Disclosure of Invention
The technical problem to be solved by the invention is as follows: a composition of probiotics and prebiotics for alleviating atopic dermatitis is provided.
In order to solve the technical problems, the invention adopts the technical scheme that:
a composition of probiotics and prebiotics with the function of relieving atopic dermatitis comprises the following raw materials in percentage by weight: lactobacillus acidophilus 1011～1014CFU/kg, Bifidobacterium lactis 1011～1014CFU/kg Bifidobacterium bifidum 1011～1014CFU/kg, Lactobacillus casei 1011～1014CFU/kg, Lactobacillus salivarius 1011～1014CFU/kg, fructo-oligosaccharide 50-500 g/kg, and galacto-oligosaccharide in balance.
The invention adopts another technical scheme that:
use of a composition of probiotics and prebiotics for ameliorating the effects of atopic dermatitis in food, health care or pharmaceutical applications.
The invention has the beneficial effects that: the composition of the probiotics and the prebiotics, which is composed of the bifidobacterium lactis, the lactobacillus acidophilus, the lactobacillus casei, the bifidobacterium bigeminy, the lactobacillus salivarius, the fructo-oligosaccharide and the galacto-oligosaccharide, has the effect of relieving atopic dermatitis through clinical research and verification; the composition of the probiotics and the prebiotics can improve the intestinal environment and restore the intestinal-skin stable state by regulating the micro-ecological balance of the intestinal tract of a human body. The high-quality prebiotics compounded by the invention can improve the colonization rate and survival rate of probiotics in intestinal tracts.
Detailed Description
In order to explain the technical content, the objects and the effects of the present invention in detail, the following description will be given with reference to the embodiments.
The most key concept of the invention is as follows: the composition of probiotic bacteria (Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, and Lactobacillus salivarius) and prebiotics (fructo-oligosaccharide, galacto-oligosaccharide) has effect in relieving atopic dermatitis.
A composition of probiotics and prebiotics for relieving atopic dermatitis function comprises the following raw materials in percentage by weight: lactobacillus acidophilus 1011～1014CFU/kg, Bifidobacterium lactis 1011～1014CFU/kg Bifidobacterium bifidum 1011～1014CFU/kg, Lactobacillus casei 1011～1014CFU/kg, Lactobacillus salivarius 1011～1014CFU/kg, fructo-oligosaccharide 50-500 g/kg, and galacto-oligosaccharide in balance.
Composition of probiotics and prebiotics the present invention has the beneficial effects that: the composition of the probiotics and the prebiotics, which is composed of the bifidobacterium lactis, the lactobacillus acidophilus, the lactobacillus casei, the bifidobacterium bifidum, the lactobacillus salivarius, the fructo-oligosaccharide and the galacto-oligosaccharide, has the effect of relieving atopic dermatitis through clinical research and verification; the composition of the probiotics and the prebiotics can improve the intestinal environment and restore the intestinal-skin stable state by regulating the micro-ecological balance of the intestinal tract of a human body. The high-quality prebiotics compounded by the invention can improve the colonization rate and survival rate of probiotics in intestinal tracts.
Lactobacillus acidophilus: lactobacillus acidophilus is mainly present in the small intestine and can release lactic acid, acetic acid and some antibiotics which act on harmful bacteria on the one hand; on the other hand, lactobacillus acidophilus relieves allergic symptoms by maintaining the balance between immune cells, and lactobacillus acidophilus L-92 increases immunoregulatory T cells and decreases too many Th2 cells, thereby helping to restore Th1/Th2 immune balance.
Bifidobacterium lactis: also called bifidobacterium animalis, which is an important physiological bacterium in the intestinal tracts of humans and animals and plays an important role in a series of physiological processes such as immunity, nutrition, digestion, protection and the like. For example, bifidobacterium lactis can reduce the pH value of the intestinal tract by producing acidic substances such as acetic acid, lactic acid and the like, decompose the coupled bile acid into free bile acid, and generate antibiotics, adhesin and the like to inhibit the growth of putrefying bacteria; in addition, the nutrient substances such as vitamins and enzymes required by the human body can be synthesized to be beneficial to the absorption of the human body. In addition, in the aspect of antianaphylaxis, bifidobacterium lactis can reduce the production of inflammatory cells or factors related to Th2 type immune reaction on the one hand and relieve allergy, such as eosinophilic granulocyte and IgE; on the other hand, certain substances such as kynurenic acid (KYNA) can be generated to relieve itching symptoms and improve the life quality of patients.
Bifidobacterium bifidum: bifidobacterium bifidum can increase the proportion of beneficial bacteria such as firmicutes, bacteroidetes and actinomycetes, reduce the proportion of harmful bacteria such as proteobacteria and clostridia, and can produce antibacterial substances to inhibit the growth of pathogenic bacteria. Researches show that the bifidobacterium bifidum can be effectively adsorbed on intestinal mucosa cells to carry out metabolic activity, generate certain antiallergic substances, reduce the IgE level and improve the allergic reaction. Clinical studies show that the allergic constitution of children is obviously reduced after pregnant mothers and infants eat bifidobacterium bifidum BGN 4.
Lactobacillus casei: the lactobacillus casei has good acid resistance and bile resistance, enhances the nonspecific resistance of a host to microbial pathogens, accelerates the elimination of the pathogens in the intestinal tract, treats the intestinal flora disorder and enhances the intestinal permeability, thereby preventing the occurrence of allergic symptoms. The lactobacillus casei can not only reduce IgE in a patient and increase the level of specific IgG, but also reduce the generation of inflammatory factors such as IL-5, IL-6, IFN-gamma and the like, and clinical research results show that the SCORAD score index of the patient is reduced, and the use frequency of local steroid drugs is also reduced.
Lactobacillus salivarius: the lactobacillus salivarius can induce specific immune response to improve innate and acquired immune response, regulate allergic constitution (immunoglobulin IgE) by stimulating immune system, reduce IgE to make it normal, and stimulate Th1 type immune response to balance Th2 type immune response caused by allergy, so as to improve allergic constitution.
Fructo-oligosaccharides and galactooligosaccharides: the galacto-oligosaccharides (GOS) and the fructo-oligosaccharides (FOS) not only belong to members of new resource foods, but also can be used as nutrition enhancers in infant formula foods, and both belong to common prebiotics in the market. Both are extracted from chicory and belong to soluble dietary fiber, because bifidobacteria and lactobacilli possess the necessary enzymes to degrade FOS and GOS for their own growth and reproduction, acting as a value-adding factor for beneficial bacteria, whereas e.coli, clostridia or streptococci do not possess enzymes to digest FOS and GOS and therefore cannot utilize FOS and GOS. In addition, a large number of clinical studies have shown that FOS and GOS administered in combination in the golden ratio of 1:9 or in combination with probiotics are effective in preventing or alleviating atopic dermatitis diseases in children.
Further, the feed comprises the following raw materials in percentage by weight: lactobacillus acidophilus 1012～1014CFU/kg, Bifidobacterium lactis 1012～1014CFU/kg Bifidobacterium bifidum 1012～1014CFU/kg, Lactobacillus casei 1012～1014CFU/kg, Lactobacillus salivarius 1012～1014CFU/kg, fructo-oligosaccharide 60-200 g/kg, and galacto-oligosaccharide in balance.
Further, the feed comprises the following raw materials in percentage by weight: lactobacillus acidophilus 1013CFU/kg, Bifidobacterium lactis 1013CFU/kg Bifidobacterium bifidum 1013CFU/kg, Lactobacillus casei 1013CFU/kg, Lactobacillus salivarius 1013CFU/kg, fructo-oligosaccharide 80-100 g/kg, and galacto-oligosaccharide in balance.
As is apparent from the above description, the amount of each bacterial species is required to achieve the effect of preventing and alleviating atopic dermatitis.
Further, the composition is granules, powder, capsules or tablets.
The invention relates to another technical scheme which is as follows:
application of composition of probiotics and prebiotics with atopic dermatitis relieving function in food, health care or pharmacy.
The products of the probiotic and prebiotic compositions in the following examples are synbiotic formulations.
Example one
The first embodiment of the invention is as follows: a composition of probiotics and prebiotics with the function of relieving atopic dermatitis comprises the following raw materials in percentage by weight: lactobacillus acidophilus 1011～1014CFU/kg, Bifidobacterium lactis 1011～1014CFU/kg Bifidobacterium bifidum 1011～1014CFU/kg, Lactobacillus casei 1011～1014CFU/kg, Lactobacillus salivarius 1011～1014CFU/kg, fructo-oligosaccharide 50-500 g/kg, and galacto-oligosaccharide in balance. Preferably, probiotics and prebioticsThe raw materials of the composition comprise the following contents: lactobacillus acidophilus 1012～1014CFU/kg, Bifidobacterium lactis 1012～1014CFU/kg Bifidobacterium bifidum 1012～1014CFU/kg, Lactobacillus casei 1012～1014CFU/kg, Lactobacillus salivarius 1012～1014CFU/kg, fructo-oligosaccharide 60-200 g/kg, and galacto-oligosaccharide in balance.
The raw materials comprise bifidobacterium lactis, bifidobacterium bifidum, lactobacillus casei, lactobacillus salivarius, lactobacillus acidophilus, fructo-oligosaccharide and galacto-oligosaccharide which are all commercially available. The raw materials are conveyed to an operation interval with the cleanliness of 30 ten thousand grade, the environmental temperature of the operation interval is controlled to be 18-26 ℃, and the relative humidity is 30-35%. The prebiotics material comprises fructo-oligosaccharide and galacto-oligosaccharide, and is dried at 60-65 deg.C, and the probiotic material comprises Bifidobacterium lactis, Bifidobacterium bifidum, Lactobacillus casei, Lactobacillus salivarius and Lactobacillus acidophilus, and is dried at 0-20 deg.C to reduce water content to below 3%. All materials comprise fructo-oligosaccharide, galacto-oligosaccharide, bifidobacterium lactis, bifidobacterium bifidum, lactobacillus casei, lactobacillus salivarius and lactobacillus acidophilus which are weighed according to the mixture ratio of the raw materials; then, the proportioned raw materials are put into the stirrer to be fully stirred until the color and luster of all the raw materials are uniform and the particle size is uniform, and the raw materials are sieved by a 100-mesh sieve; and finally, packaging the mixture by an automatic filling machine according to the product specification of 2 g/bag to obtain the synbiotics preparation.
Example two
The second embodiment of the present invention is a synbiotic preparation having a function of alleviating atopic dermatitis, which is different from the first embodiment in that:
the composition comprises the following raw materials in each kilogram of probiotics and prebiotics composition: lactobacillus acidophilus 1013CFU, Bifidobacterium lactis 1013CFU, Bifidobacterium bifidum 1013CFU, Lactobacillus casei 1013CFU, Lactobacillus salivarius 1013CFU, fructo-oligosaccharide 100g, and galacto-oligosaccharide in balance. In this example, the Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium bifidum, Lactobacillus casei and Lactobacillus salivarius are describedThe ratio of the number of bacteria is 1: 1: 1: 1: 1.
EXAMPLE III
The third embodiment of the present invention is a synbiotics preparation with a function of alleviating atopic dermatitis, which is different from the first embodiment in that:
the composition comprises the following raw materials in each kilogram of probiotics and prebiotics composition: lactobacillus acidophilus 1013CFU, Bifidobacterium lactis 1013CFU, Bifidobacterium bifidum 1013CFU, Lactobacillus casei 1013CFU, Lactobacillus salivarius 1013CFU, fructo-oligosaccharide 90g, and galacto-oligosaccharide in balance.
Example four
The fourth embodiment of the present invention is a synbiotic preparation having a function of alleviating atopic dermatitis, which is different from the first embodiment in that:
the composition comprises the following raw materials in each kilogram of probiotics and prebiotics composition: lactobacillus acidophilus 1013CFU, Bifidobacterium lactis 1013CFU, Bifidobacterium bifidum 1013CFU, Lactobacillus casei 1013CFU, Lactobacillus salivarius 1013CFU, fructo-oligosaccharide 80g, and galacto-oligosaccharide in balance.
EXAMPLE five
The fifth embodiment of the present invention is a synbiotics preparation having a function of alleviating atopic dermatitis, which is different from the first embodiment in that:
the composition comprises the following raw materials in percentage by weight per kilogram: lactobacillus acidophilus 1014CFU, Bifidobacterium lactis 1011CFU, Bifidobacterium bifidum 1011CFU, Lactobacillus casei 1014CFU, Lactobacillus salivarius 1011CFU, fructo-oligosaccharide 60g, and galacto-oligosaccharide in balance.
EXAMPLE six
The sixth embodiment of the present invention is a synbiotics preparation having a function of alleviating atopic dermatitis, which is different from the first embodiment in that:
the composition comprises the following raw materials in each kilogram of probiotics and prebiotics composition: lactobacillus acidophilus 1011CFU, Bifidobacterium lactis 1014CFU, Bifidobacterium bifidum 1014CFU, Lactobacillus casei 1011CFU, Lactobacillus salivarius 1014CFU, fructo-oligosaccharide 50g, and galacto-oligosaccharide in balance.
EXAMPLE seven
The seventh embodiment of the present invention is a synbiotics preparation having a function of alleviating atopic dermatitis, which is different from the first embodiment in that:
the composition comprises the following raw materials in each kilogram of probiotics and prebiotics composition: lactobacillus acidophilus 1011CFU, Bifidobacterium lactis 1014CFU, Bifidobacterium bifidum 1014CFU, Lactobacillus casei 1011CFU, Lactobacillus salivarius 1011CFU, 500g of fructo-oligosaccharide and the balance of galacto-oligosaccharide.
Example eight
The eighth embodiment of the present invention is a synbiotic preparation having a function of alleviating atopic dermatitis, which is different from the first embodiment in that:
the composition comprises the following raw materials in each kilogram of probiotics and prebiotics composition: lactobacillus acidophilus 1014CFU, Bifidobacterium lactis 1012CFU, Bifidobacterium bifidum 1014CFU, Lactobacillus casei 1012CFU, Lactobacillus salivarius 1014CFU, fructo-oligosaccharide 200g, and galacto-oligosaccharide in balance.
Example nine
The ninth embodiment of the present invention is a synbiotics preparation having a function of alleviating atopic dermatitis, which is different from the first embodiment in that:
the composition comprises the following raw materials in each kilogram of probiotics and prebiotics composition: lactobacillus acidophilus 1012CFU, Bifidobacterium lactis 1014CFU, Bifidobacterium bifidum 1012CFU, Lactobacillus casei 1014CFU, Lactobacillus salivarius 1012CFU, fructo-oligosaccharide 60g, and galacto-oligosaccharide in balance.
Clinical research experiment
The synbiotic preparation of the second example is subjected to clinical research experiments, which are as follows:
200 atopic dermatitis patients were recruited and randomized into 2 groups (ages 18-50) of 100 persons each, two placebo groups: administering a maltodextrin group; test groups: taking the synbiotics preparation of the invention, the number of the finally finished test persons is 68 persons in a placebo group and 72 persons in a test group respectively, the test is a random double-blind control test, all sample packages are packaged by tinfoil inner packaging paper and are subjected to grouping marking to ensure double blindness, all subjects sign informed consent and receive the same standard drug treatment scheme before the test, the test duration is 8 weeks, wherein the intervention time is 2 weeks, the 4 th week and the 8 th week are re-diagnosed, and the SCORAD value, total IgE and eosinophilic granulocyte number change condition of each group of subjects are evaluated in a baseline period, the 2 nd week, the 4 th week and the 8 th week respectively.
Atopic dermatitis score index, coring atopic dermatitis index, SCORAD: in clinical applications, the SCORAD score is widely used in clinical studies of AD (atopic dermatitis), and is considered as the "gold standard" for assessing the severity of the AD condition. The SCORAD scoring criteria included three major components: the objective signs part includes the area of the lesion (a) and the severity of the lesion (B), and the subjective symptoms include itching and the degree of sleep impact (C). The severity rating of AD can be determined from objective and subjective sign scores: the grade is mild from 0 to 24, severe from 25 to 50 and severe from 51 to 103.
The basic parameters of the experimenter are shown in table 1:
TABLE 1 conditions of the basic parameters of the test subjects
The change in the score index of atopic dermatitis in the two groups of atopic dermatitis patients at different time periods is shown in table 2:
TABLE 2 SCORAD index changes in two groups of atopic dermatitis patients at different time periods
Note that: EMM, an interested marginal mean, estimating a boundary mean; SE, standard error. An analysis of variance method using repeated measurements of the samples was used.
The changes in IgE and eosinophil counts in two groups of atopic dermatitis patients at different time periods are shown in table 3:
TABLE 3 change in IgE and eosinophil counts in two groups of atopic dermatitis patients at different time periods
The test results in tables 2 and 3 show that the score of atopic dermatitis patients in the test group at the 8 th week is significantly reduced compared to the placebo group; the mean IgE levels were also significantly reduced at week 2 and 4 of the experiment; although there were no statistical differences in eosinophil counts between the week 2, week 4 and week 8 groups, the values between both groups tended to decrease significantly over time compared to the baseline. The research result shows that although there is no positive-negative relation between the score table of the SCORAD index of atopic dermatitis and IgE and eosinophil, each index reflects the overall improvement of atopic dermatitis.
The test results of other examples are similar to those of the second example, and are not listed here.
The composition can be prepared into granules, powder, capsules or tablets, and can be applied to food, health care or pharmacy.
In conclusion, the probiotic and prebiotic composition which is composed of bifidobacterium lactis, lactobacillus acidophilus, lactobacillus casei, bifidobacterium bifidum, lactobacillus salivarius, fructo-oligosaccharide and galacto-oligosaccharide and has the function of relieving atopic dermatitis is proved to have the effect of relieving atopic dermatitis by clinical research; the synbiotic preparation can improve the intestinal environment and restore the intestinal-skin stable state by regulating the micro-ecological balance of the intestinal tract of a human body. The high-quality prebiotics compounded by the invention can improve the colonization rate and survival rate of probiotics in intestinal tracts.
The above description is only an embodiment of the present invention, and not intended to limit the scope of the present invention, and all equivalent modifications made by the present invention in the specification or directly or indirectly applied to the related technical field are included in the scope of the present invention.
Claims (5)
1. The composition of probiotics and prebiotics for relieving the function of atopic dermatitis is characterized by comprising the following raw materials in percentage by weight: lactobacillus acidophilus 1011～1014CFU/kg, Bifidobacterium lactis 1011～1014CFU/kg Bifidobacterium bifidum 1011～1014CFU/kg, Lactobacillus casei 1011～1014CFU/kg, Lactobacillus salivarius 1011～1014CFU/kg, fructo-oligosaccharide 50-500 g/kg, and galacto-oligosaccharide in balance.
2. The composition of probiotics to alleviate the function of atopic dermatitis according to claim 1, comprising the following raw materials in the amount: lactobacillus acidophilus 1012～1014CFU/kg, Bifidobacterium lactis 1012～1014CFU/kg Bifidobacterium bifidum 1012～1014CFU/kg, Lactobacillus casei 1012～1014CFU/kg, Lactobacillus salivarius 1012～1014CFU/kg, fructo-oligosaccharide 60-200 g/kg, and galacto-oligosaccharide in balance.
3. The composition of probiotics to alleviate the function of atopic dermatitis according to claim 2, comprising the following raw materials in the amount: lactobacillus acidophilus 1013CFU/kg, Bifidobacterium lactis 1013CFU/kg Bifidobacterium bifidum 1013CFU/kg, Lactobacillus casei 1013CFU/kg, Lactobacillus salivarius 1013CFU/kg, fructo-oligosaccharide 80-100 g/kg, and galacto-oligosaccharide in balance.
4. The composition of probiotics and prebiotics for relieving atopic dermatitis function according to claim 1, wherein the composition is granule, powder, capsule or tablet.
5. Use of a composition of probiotics to alleviate the function of atopic dermatitis according to any one of claims 1 to 4, characterized in that it is used in food, health care or pharmaceutical.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010413680.5A CN111528479A (en) | 2020-05-15 | 2020-05-15 | Probiotics and prebiotics composition for relieving atopic dermatitis function and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010413680.5A CN111528479A (en) | 2020-05-15 | 2020-05-15 | Probiotics and prebiotics composition for relieving atopic dermatitis function and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111528479A true CN111528479A (en) | 2020-08-14 |
Family
ID=71969269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010413680.5A Pending CN111528479A (en) | 2020-05-15 | 2020-05-15 | Probiotics and prebiotics composition for relieving atopic dermatitis function and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111528479A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112515171A (en) * | 2020-12-18 | 2021-03-19 | 北京海思未来健康科技有限公司 | Fluid-supplementing probiotic composition and application thereof |
| CN113995775A (en) * | 2021-11-01 | 2022-02-01 | 青岛蔚蓝生物股份有限公司 | A probiotic foot film with foot protection effect and preparation method thereof |
| CN114304642A (en) * | 2021-11-25 | 2022-04-12 | 青岛康益生物科技有限公司 | A probiotic product for allergy |
| CN114401728A (en) * | 2021-10-29 | 2022-04-26 | 海普诺凯营养品有限公司 | Composition of prebiotics and probiotic compound and application thereof |
| CN114984061A (en) * | 2022-07-15 | 2022-09-02 | 比菲德(北京)生物科技有限公司 | Probiotic powder for relieving autoimmune diseases and application thereof |
| EP4151217A1 (en) * | 2021-09-15 | 2023-03-22 | Alexander Werz S.R.L. | Combined topical and oral compositions for the treatment of gut-skin dysbiosis |
| CN116286371A (en) * | 2023-03-07 | 2023-06-23 | 深圳零一生命科技有限责任公司 | Freeze-drying protective agent formula for improving freeze-drying effect of strain |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103037876A (en) * | 2010-03-08 | 2013-04-10 | 益生菌股份公司 | Composition comprising probiotic bacteria for use in the treatment of immune disorders |
| CN103169733A (en) * | 2011-12-26 | 2013-06-26 | 浙江贝因美科工贸股份有限公司 | Compound probiotic, application thereof for treating anaphylactic diseases and allergy free probiotic electuary for pregnant and lying-in women |
| CN110214014A (en) * | 2016-07-18 | 2019-09-06 | 拜纽研发有限公司 | The purposes in atopic dermatitis is being treated and/or prevented to probiotics |
| CN110710627A (en) * | 2018-07-12 | 2020-01-21 | 序瑞生物科技(上海)有限公司 | Functional probiotic solid beverage and preparation method thereof |
-
2020
- 2020-05-15 CN CN202010413680.5A patent/CN111528479A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103037876A (en) * | 2010-03-08 | 2013-04-10 | 益生菌股份公司 | Composition comprising probiotic bacteria for use in the treatment of immune disorders |
| CN103169733A (en) * | 2011-12-26 | 2013-06-26 | 浙江贝因美科工贸股份有限公司 | Compound probiotic, application thereof for treating anaphylactic diseases and allergy free probiotic electuary for pregnant and lying-in women |
| CN110214014A (en) * | 2016-07-18 | 2019-09-06 | 拜纽研发有限公司 | The purposes in atopic dermatitis is being treated and/or prevented to probiotics |
| CN110710627A (en) * | 2018-07-12 | 2020-01-21 | 序瑞生物科技(上海)有限公司 | Functional probiotic solid beverage and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 王磊等: "益生菌与过敏性疾病的预防和治疗进展", 《中国药事》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112515171A (en) * | 2020-12-18 | 2021-03-19 | 北京海思未来健康科技有限公司 | Fluid-supplementing probiotic composition and application thereof |
| EP4151217A1 (en) * | 2021-09-15 | 2023-03-22 | Alexander Werz S.R.L. | Combined topical and oral compositions for the treatment of gut-skin dysbiosis |
| CN114401728A (en) * | 2021-10-29 | 2022-04-26 | 海普诺凯营养品有限公司 | Composition of prebiotics and probiotic compound and application thereof |
| CN114401728B (en) * | 2021-10-29 | 2024-05-31 | 澳优乳业（中国）有限公司 | Composition of prebiotics and probiotics compound and application thereof |
| CN113995775A (en) * | 2021-11-01 | 2022-02-01 | 青岛蔚蓝生物股份有限公司 | A probiotic foot film with foot protection effect and preparation method thereof |
| CN113995775B (en) * | 2021-11-01 | 2023-08-29 | 青岛蔚蓝生物股份有限公司 | A kind of probiotic foot mask with foot protection effect and preparation method thereof |
| CN114304642A (en) * | 2021-11-25 | 2022-04-12 | 青岛康益生物科技有限公司 | A probiotic product for allergy |
| CN114984061A (en) * | 2022-07-15 | 2022-09-02 | 比菲德(北京)生物科技有限公司 | Probiotic powder for relieving autoimmune diseases and application thereof |
| CN116286371A (en) * | 2023-03-07 | 2023-06-23 | 深圳零一生命科技有限责任公司 | Freeze-drying protective agent formula for improving freeze-drying effect of strain |
| CN116286371B (en) * | 2023-03-07 | 2023-07-18 | 深圳零一生命科技有限责任公司 | Freeze-drying protective agent formula for improving freeze-drying effect of strain |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111528479A (en) | Probiotics and prebiotics composition for relieving atopic dermatitis function and application | |
| US10286001B2 (en) | Use of purified 2′-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics | |
| JP6444358B2 (en) | Pharmaceutical composition containing pediococcus and method for reducing symptoms of digestive syndrome | |
| De Vrese et al. | Probiotics and prebiotics: effects on diarrhea | |
| RU2609838C2 (en) | Composition for preventing and/or treating skin conditions and skin diseases | |
| Kullen et al. | The delivery of probiotics and prebiotics to infants | |
| JP2021527104A (en) | Formulation for the treatment of inflammatory bowel disease using whole plant fiber extract derived from sugar cane | |
| US20100166721A1 (en) | Probotic compositions and uses thereof | |
| US20110165127A1 (en) | Dairy-derived probiotic compositions and uses thereof | |
| TW202002963A (en) | Compositions and methods for biosynthetic preparation of UROLITHIN compounds and use thereof | |
| JP2008520640A (en) | Probiotic bacterial composition and its use to prevent and / or treat respiratory conditions and / or respiratory infections and improve bowel function | |
| JP2016520305A (en) | Association of Lactonospirae bacteria and body weight in gastrointestinal microbiota | |
| CN106036911A (en) | Probiotics diet composition and functional food for regulating blood glucose level | |
| CN111264879A (en) | Synbiotic and application thereof | |
| CN111528486A (en) | Composition containing lactoferrin | |
| Vijaya Kumar et al. | Beneficial effects of probiotics and prebiotics on human health | |
| US20220193155A1 (en) | Microbial compositions and methods for greater tolerability and prolonged shelf life | |
| CN113750113A (en) | Composition of probiotics and prebiotics and application thereof | |
| CN112806577B (en) | Prebiotic probiotic synergistic combinations for butyric acid production | |
| Chikkamath et al. | The role of probiotics, prebiotics and synbiotic on human health and disease-A review | |
| Schmitt et al. | Effect of xylitol on the growth of Lactobacillus acidophilus for food and pharmaceutical applications Efeito do xilitol no crescimento do Lactobacillus acidophilus em alimentos e aplicações farmacêuticas | |
| KR102687185B1 (en) | A composition as a prebiotic for improving intestinal microflora containing polygalacturonic acid | |
| Surendran et al. | Role of Synbiotics in Gastrointestinal Disorders | |
| Solkar et al. | Pre and Probiotics In Paediatrics | |
| Singh | Chapter-7 Functional Foods: Probiotics and Prebiotics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200814 |